Order byBest matchMost fresh

Biotech Stocks Fall

Digest more
Top News
Impacts
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slowe...
From U.S. News & World Report
Biotech investors are reeling after the sudden departure of Dr. Peter Marks, a pivotal figure in the U.S. Food and Drug Administration.
From Wall Street Journal

Read more on News Digest

Biotech Stocks Tumble on Reports FDA's Top Vaccine Regulator to Leave
As director of the FDA's Center for Biologics Evaluation and Research, Marks has publicly supported programs that expedited the development of rare disease treatments and gene therapies during his tenure.
Biotech Stocks Fall As FDA's Peter Marks Resigns
Vaccine and biotech stocks plummeted after Peter Marks, a top regulator at the US Food and Drug Administration, resigned due to friction with Health and Human Services Secretary Robert F. Kennedy Jr.
Fiery Resignation of Top FDA Official Sparks Biotech Selloff
Dr. Peter Marks, who led the FDA’s Center for Biologics Evaluation and Research, was perhaps the best-known official within the agency.
Heard on the Street: Biotech Investors Rush for the Exits After FDA Official Resigns
Biotech investors are reeling after the sudden departure of Dr. Peter Marks, a pivotal figure in the U.S. Food and Drug Administration. Marks, who played a crucial role in Operation Warp Speed and cha
Trump Administration Highlights: Nearly All Institute of Peace Staff in the U.S. Are Fired
Nearly all of the U.S. staff members at the Institute of Peace have been fired, a sharp escalation of the Trump administration and Elon Musk’s efforts to eliminate the government-funded independent nonprofit,
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter's winners and losers.
Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
Biotech stocks plunge after Dr. Peter Marks resigns from FDA, citing disputes with RFK Jr. over vaccines and drug approvals. Investors fear regulatory uncertainty.
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Recursion Pharmaceuticals uses artificial intelligence (AI) in its proprietary operating system to match new compounds against a vast library of human genes in order to come up with new therapies. Currently, Recursion has trials underway for a variety of neurological diseases, as well as some cancers.
Biotech stocks slide as Marks resignation seen being negative for sector
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug
Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other best mid cap biotech stocks to buy.
Explore more
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of Moderna, Novavax and other biotech companies fell after FDA official Peter Marks’s resignation in protest of Robert F. Kennedy Jr.
+10 relevant news
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Dow Soars Past 42,000 as Biotech Stocks Lead Rebound
Stocks rallied with the Dow gaining 417 points while biotech and banking stocks surged. However, global markets slumped amid tariff concerns and inflation fears.
2 No-Brainer Biotech Stocks to Buy Right Now
Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue to gain after that company moves into the product commercialization stage.
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Is Precigen (PGEN) The Hot Biotech Stock Under $5?
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Hosted on MSN7h
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Fortress Biotech shares have lost about 20.5% since the ...
Feedback
"%24%20is%20not%20defined","Stack":"ReferenceError%3A%20%24%20is%20not%20defined%0A%20%20%20%20at%20self%3A68%3A3529%0A%20%20%20%20at%20self%3A68%3A3535","Meta":"self","Line":"68","Char":"3529"